Assessing cognition in patients with early Alzheimer’s disease – an experts views on the new FDA guidance - On Biology

Assessing cognition in patients with early Alzheimer’s disease – an experts views on the new FDA guidance - On Biology

On Biology

John Harrison

John Harrison is an Associate Professor with the Alzheimer Center at the VUmc in Amsterdam, Visiting Professor with the IoPPN at Kings College London, and Principal Consultant at Metis Cognition Ltd. He has two decades' experience of assisting pharmaceutical and biotechnology companies with the selection and successful integration of cognitive testing into their drug development programs

Find John on LinkedIn and Academia.

Assessing cognition in patients with early Alzheimer’s disease – an experts views on the new FDA guidance

A recent commentary published in Alzheimer's Research and Therapy highlights the benefits and flaws of the new FDA guidelines for Alzheimer's drug development. In this blog John Harrison, an associate professor at the Alzheimer Center at the VU Medical Center in Amsterdam, sheds some light on the new FDA guidelines and what this means for the future of Alzheimer's drug development.

John Harrison 2 Jul 2018

What is early stage Alzheimer’s and why is it so difficult to diagnose?